Caribou Biosciences, Inc.
CRBU
$1.86
$0.105.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -19.00% | -72.45% | -70.31% | -71.01% | -66.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.00% | -72.45% | -70.31% | -71.01% | -66.85% |
| Cost of Revenue | -6.60% | -45.58% | -59.95% | -68.67% | -65.71% |
| Gross Profit | 0.92% | 16.27% | 53.61% | 67.63% | 65.17% |
| SG&A Expenses | -12.84% | -11.18% | -5.99% | 20.79% | 22.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.08% | -6.13% | 5.17% | 16.92% | 22.84% |
| Operating Income | 11.60% | -9.38% | -24.42% | -43.04% | -51.27% |
| Income Before Tax | -6.23% | -33.29% | -28.51% | -46.37% | -56.56% |
| Income Tax Expenses | -104.66% | -104.66% | -104.66% | -104.66% | 175.71% |
| Earnings from Continuing Operations | -6.08% | -33.07% | -28.29% | -46.08% | -56.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.08% | -33.07% | -28.29% | -46.08% | -56.65% |
| EBIT | 11.60% | -9.38% | -24.42% | -43.04% | -51.27% |
| EBITDA | 12.26% | -9.05% | -24.55% | -44.04% | -52.69% |
| EPS Basic | -2.72% | -28.60% | -11.68% | -14.03% | -10.12% |
| Normalized Basic EPS | 5.36% | -19.01% | -11.46% | -13.84% | -10.12% |
| EPS Diluted | -2.72% | -28.60% | -11.68% | -14.03% | -10.12% |
| Normalized Diluted EPS | 5.36% | -19.01% | -11.46% | -13.84% | -10.12% |
| Average Basic Shares Outstanding | 3.24% | 4.40% | 12.91% | 22.54% | 34.09% |
| Average Diluted Shares Outstanding | 3.24% | 4.40% | 12.91% | 22.54% | 34.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |